MEDICINAL PHYTOCHEMICALS TARGETING TOBACCO INDUCED ORAL DYSBIOSIS AND BIOFILM FORMATION: MECHANISMS, THERAPEUTIC POTENTIAL, AND FUTURE PERSPECTIVES

Abstract

Tobacco consumption is a major modifiable risk factor for oral diseases, particularly periodontitis, owing to its profound effects on the oral microbiome and biofilm development. Exposure to tobacco smoke disrupts microbial homeostasis, resulting in oral dysbiosis characterized by enrichment of pathogenic species such as Porphyromonas gingivalis, Fusobacterium nucleatum, and Streptococcus mutans. These microbial alterations enhance bacterial adhesion, quorum sensing, extracellular polymeric substance production, and biofilm maturation, thereby increasing resistance to host immune responses and conventional antimicrobial therapies. Recent advances have highlighted medicinal plants as promising adjunctive strategies for preventing and managing tobacco-associated oral biofilm infections. Plant compounds like flavonoids, polyphenols, terpenoids, alkaloids, catechins, and phenolic acids possess broad-spectrum antibacterial, antioxidant, anti-inflammatory, and antibiofilm properties owing to their ability to affect different phases of biofilm formation such as bacterial adherence, extra-cellular matrix synthesis, quorum sensing, and virulence factors. This review comprehensively examines the molecular mechanisms underlying tobacco-induced oral dysbiosis and biofilm formation while critically evaluating current evidence on plant-derived antibiofilm agents and their therapeutic potential in oral healthcare. In addition, emerging technologies such as nanotechnology-based drug delivery systems and microbiome-targeted approaches are discussed as strategies to improve the clinical translation of phytotherapeutics. Despite encouraging preclinical evidence, significant challenges remain, including variability in phytochemical composition, limited bioavailability, lack of standardized formulations, and insufficient high-quality clinical trials. Future research should focus on mechanistic investigations, optimized delivery platforms, and well-designed clinical studies to validate medicinal plants as evidence-based therapeutics for tobacco-associated oral biofilm diseases. Collectively, integrating phytochemicals with modern precision oral healthcare may provide a promising avenue for restoring microbial homeostasis and improving periodontal health in tobacco users.